Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073411 · ClinicalTrials.gov registry record · Phase 3
Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression
A Phase 3 study of Depression, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 675
- Enrollment target
- 1
- Study location
NCT00073411 is a Phase 3 study of Depression that has completed, run by Eli Lilly and Company. The registered enrollment target is 675 participants, below the 785-participant average among 679 other Depression trials with a reported enrollment target (14% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00073411, a Phase 3 study of Depression, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 675 participants
- Enrollment target
- 1
- Study location
Study Summary
The purposes of this study are to determine: * The safety of duloxetine and any side effects that might be associated with it. * How duloxetine compares to escitalopram and placebo (an inactive ingredient)
Conditions Studied
Interventions
- DRUG placebo
- DRUG duloxetine
- DRUG escitalopram
Study Locations (1)
Ohio
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician. - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 675 participants |
| Start Date | 2003-11 |
| Est. Completion | 2005-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073411
The ClinicalTrials.gov registry entry for NCT00073411 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 675 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 785-participant average among 679 other Depression trials with a reported enrollment target (14% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Depression appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT00073411 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00073411 about?
NCT00073411 is a clinical study titled "Duloxetine Compared to Escitalopram and Placebo in the Treatment of Patients With Depression". The purposes of this study are to determine: * The safety of duloxetine and any side effects that might be associated with it. * How duloxetine compares to escitalopram and placebo (an inactive ingredient)
What is the current status of trial NCT00073411?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 675 participants. The study started on 2003-11. Estimated completion is 2005-05.
What conditions does trial NCT00073411 study?
This clinical trial studies the following conditions: Depression.
What interventions are being tested in trial NCT00073411?
The interventions under investigation include: placebo (DRUG), duloxetine (DRUG), escitalopram (DRUG).
Who is sponsoring clinical trial NCT00073411?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00073411 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Behavioral Activation Delivered Via Home-based Telehealth to Improve Functioning in Cardiovascular Disease Patients Recently Discharged From Inpatient Care
RECRUITING · Phase 3
-
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
RECRUITING · Phase 3
-
A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.
RECRUITING · Phase 3
-
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
RECRUITING · Phase 3
-
Creatine for Depressed Male and Female Methamphetamine Users
RECRUITING · Phase 3
-
E-Mindfulness Approaches for Living After Breast Cancer
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.